Garrett M. Brodeur Laboratory

Led by Garrett M. Brodeur, MD researchers in the Brodeur Laboratory are focused on identifying the major genes, proteins and oncogenic pathways that are responsible for the malignant transformation and disease progression of neuroblastomas. The ultimate goal of the research conducted in this laboratory is to develop targeted cancer therapies to treat neuroblastomas that are more effective and less toxic than current neuroblastoma treatment options.

Selected Publications

Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Lett. 2016 Mar 28;372(2):179-86.
Iyer R, Wehrmann L, Golden RL, Naraparaju K, Croucher JL, MacFarland SP, Guan P1, Kolla V, Wei G2, Cam N, Li G, Hornby Z, Brodeur GM.

Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas. Oncotarget. 2016 Feb 16.
Naraparaju K, Kolla V, Zhuang T, Higashi M, Iyer R, Kolla S, Okawa ER, Blobel GA, Brodeur GM.

Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG.